Integrative "omic" analysis for tamoxifen sensitivity through cell based models

Liming Weng, Dana Ziliak, Bonnie LaCroix, Paul Geeleher, R. Stephanie Huang

Research output: Contribution to journalArticlepeer-review

7 Scopus citations


It has long been observed that tamoxifen sensitivity varies among breast cancer patients. Further, ethnic differences of tamoxifen therapy between Caucasian and African American have also been reported. Since most studies have been focused on Caucasian people, we sought to comprehensively evaluate genetic variants related to tamoxifen therapy in African-derived samples. An integrative "omic" approach developed by our group was used to investigate relationships among endoxifen (an active metabolite of tamoxifen) sensitivity, SNP genotype, mRNA and microRNA expressions in 58 HapMap YRI lymphoblastoid cell lines. We identified 50 SNPs that associate with cellular sensitivity to endoxifen through their effects on 34 genes and 30 microRNA expression. Some of these findings are shared in both Caucasian and African samples, while others are unique in the African samples. Among gene/microRNA that were identified in both ethnic groups, the expression of TRAF1 is also correlated with tamoxifen sensitivity in a collection of 44 breast cancer cell lines. Further, knock-down TRAF1 and over-expression of hsa-let-7i confirmed the roles of hsa-let-7i and TRAF1 in increasing tamoxifen sensitivity in the ZR-75-1 breast cancer cell line. Our integrative omic analysis facilitated the discovery of pharmacogenomic biomarkers that potentially affect tamoxifen sensitivity.

Original languageEnglish (US)
Article numbere93420
JournalPloS one
Issue number4
StatePublished - Apr 3 2014
Externally publishedYes


Dive into the research topics of 'Integrative "omic" analysis for tamoxifen sensitivity through cell based models'. Together they form a unique fingerprint.

Cite this